In ----, according to data published by OSMED, pharmaceutical spending in Italy amounted to EUR--.--bn (USD--.--bn), of which --.- was reimbursed by the SSN. On average, for every Italian citizen, spending on drugs amounted to about EUR---. ...Government spending accounts for a large proportion of pharmaceutical and healthcare spending and enforcing price cuts and controls on medicines seems a relatively easy way to rein in costs in the face of an escalating debt burden. Furthermore, while fiscal expenditure has continued to rise, this has not benefited the healthcare sector, as funds have been diverted towards bank bailouts, necessitating a subjective modification of the pharmaceutical forecast for Italy, particularly as our Pharmaceutical Expenditure Forecast Model uses fiscal expenditure as a variable. The decline in pharmaceutical expenditure by the national health service, Servizio Sanitario Nazionale ...Furthermore, while fiscal expenditure has continued to rise, this has not benefited the healthcare sector, as funds have been diverted towards bank bailouts, necessitating a subjective modification of the pharmaceutical forecast for Italy, particularly as our Pharmaceutical Expenditure Forecast Model uses fiscal expenditure as a variable. The decline in pharmaceutical expenditure by the national health service, Servizio Sanitario Nazionale
...BMI View: Prescription drugmakers operating in Italy will continue to face revenue challenges as spending by the country s national healthcare service, Servizio Sanitario Nazionale (SSN), continues to be restricted. The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. ...BMI View: Prescription drugmakers operating in Italy will continue to face revenue challenges as spending by the country s national healthcare service, Servizio Sanitario Nazionale (SSN), continues to be restricted. The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. This will continue to negatively impact the healthcare sector and particularly pharmaceutical spending, a large beneficiary of public funds. ...The government remains committed to remaining under the - of GDP budget deficit limit and using any additional fiscal capacity to ease the tax burden instead of ramping up spending. This will continue to negatively impact the healthcare sector and particularly pharmaceutical spending, a large beneficiary of public funds.
...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...
...